RxDoctor Payments Data

Monique Dickinson, NP

Nurse Practitioner · Chanute, KSNPI 1336681386

Payments from drug & device makers

$1,241in general payments, 2019–2025

Across 65 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$505
  • Lilly USA, LLC$155
  • Dexcom, Inc.$119
  • AstraZeneca$99
  • Medtronic$78
  • Bayer$75
  • plus $209 from 9 others

What the payments were for

  • Food & beverage$1,241100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,241 in reported general payments places this provider in the 75th percentile of 1,326 nurse practitioner providers in Kansas.

See all nurse practitioner providers in Kansas

Medicare billing

Part B allowed, 2024
$49,286
Medicare patients
179
Services billed
1,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide191$234,240
Tresiba Flextouch U-200Insulin Degludec126$127,750
JardianceEmpagliflozin111$85,736
FarxigaDapagliflozin Propanediol84$63,303
MounjaroTirzepatide50$60,950
RybelsusSemaglutide56$55,986
TrulicityDulaglutide45$52,372
Tresiba Flextouch U-100Insulin Degludec47$30,545
Soliqua 100-33Insulin Glargine/Lixisenatide25$27,918
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog30$24,928
Fiasp FlextouchInsulin Aspart (Niacinamide)19$20,800
Novolog FlexpenInsulin Aspart69$17,492
JanuviaSitagliptin Phosphate26$16,151
Humalog Kwikpen U-200Insulin Lispro14$16,052
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$12,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$505$290,226247 claims
Lilly USA, LLCMounjaro, Trulicity$155$113,32195 claims
Boehringer IngelheimJardiance$20$85,736111 claims
AstraZenecaFarxiga$99$63,30384 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$34$27,91825 claims
BayerKerendia$75$9,41714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,326 nurse practitioner providers in Kansas.

Other nurse practitioner in Chanute

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →